LAFAYETTE, La. - The federal judge overseeing the Actos multidistrict litigation on June 20 issued a final opinion finding that drug manufacturer Takeda Pharmaceuticals International Inc. and related entities acted in bad faith in failing to preserve or in destroying evidence and ordered the company to pay for expenses, including attorney fees (In Re: Actos $(Pioglitazone$) Products Liability Litigation, MDL Docket No. 2299, W.D. La., Lafayette Div.).